3β,7α-Dihydroxyandrost-5-en-17-on | 53-00-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β,7α-Dihydroxyandrost-5-en-17-on
• 英文别名: 5-androstene-3beta,7alpha-diol-17beta-one；(3S,7S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• CAS: 53-00-9；2487-48-1；7522-54-5；62357-03-3
• 化学式: C₁₉H₂₈O₃
• 分子量: 304.43
• InChiKey: OLPSAOWBSPXZEA-FEBXTQPISA-N

物化性质

• 熔点：
  181.5-183.5 °C(Solv: acetone (67-64-1))
• 沸点：
  473.3±45.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于乙醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

制备方法与用途

用途：用于制备医药中间体。

文献信息

• Transdermal Steriod for Formulation
  申请人：Murray Robert James

  公开号：US20070231373A1

  公开（公告）日：2007-10-04

  Compounds of formula (I) (in which R 1 ; R 2 , R 3 and R 4 are the same as or different from each other and each represents an oxo group, a hydroxy group, a mercapto group, a hydrogen atom, a halogen atom, an alkoxy group or an aryloxy group; and the dotted line indicates that there may be a single or double bond between one of the respective pairs of carbon atoms) and esters thereof can be administered by transdermal administration. They are particularly effective when applied as a patch, preferably with an adhesive comprising a copolymer of from 40 to 60% by weight of methoxyethyl acrylate, from 30 to 40% by weight of lauryl acrylate or lauryl methacrylate and from 10 to 25% by weight of a polar monomer.
• MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS
  申请人：Wülfert Ernst

  公开号：US20100137270A1

  公开（公告）日：2010-06-03

  A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2.
• Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways
  申请人：WULFERT ERNST

  公开号：US20130023504A1

  公开（公告）日：2013-01-24

  A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2.
• US8148355B2
  申请人：——

  公开号：US8148355B2

  公开（公告）日：2012-04-03
• [EN] MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS<br/>[FR] MODULATION DES VOIES MÉTABOLIQUES DE LA PROSTAGLANDINE/CYCLOOXYGÉNASE
  申请人：HUNTER FLEMING LTD

  公开号：WO2008065408A2

  公开（公告）日：2008-06-05

  (EN) A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2. The compounds are 7-hydroxy-steroids or condensed indoles.(FR) Une variété de maladies et troubles associés aux voies métaboliques impliquées dans les activités de la cyclooxygénase et la synthèse de prostaglandines, par exemple le diabète mellitus de type 2 et ses séquelles, les maladies vasculaires ischémiques, la douleur associée à l'inflammation, les conditions inflammatoires cutanées, la blessure médullaire, la neuropathie périphérale, la sclérose en plaques, l'affection abdominale inflammatoire et la polyarthrite rhumatoïde, ainsi que divers types de cancers peuvent être traités ou prévenus par l'utilisation d'un agent qui augmente sélectivement la production de la 15-désoxy-prostaglandine J2.